Press Releases

May 08, 2020

Summary Toggle Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

RESEARCH TRIANGLE PARK, N.C. , May 08, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from
May 05, 2020

Summary Toggle Fennec Announces Closing of Public Offering

RESEARCH TRIANGLE PARK, N.C. , May 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC) (TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate ) for the prevention of platinum-induced ototoxicity from
April 30, 2020

Summary Toggle Fennec Announces Pricing of Public Offering

RESEARCH TRIANGLE PARK, N.C. , April 30, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from
April 29, 2020

Summary Toggle Fennec Announces Proposed Public Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C. , April 29, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from
April 13, 2020

Summary Toggle Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA) Target Action Date of August 10, 2020 ~ Research Triangle Park, N.C.
March 05, 2020

Summary Toggle Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™

RESEARCH TRIANGLE PARK, N.C. , March 05, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in
February 28, 2020

Summary Toggle Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children RESEARCH TRIANGLE PARK, N.C. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the company’s Marketing
February 14, 2020

Summary Toggle Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S. underway for potential launch of PEDMARK TM , if approved, in the second half of 2020 Solid financial position with $13.7 million and no debt and the option
February 11, 2020

Summary Toggle Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

PEDMARK™ is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children RESEARCH TRIANGLE PARK, N.C. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission